Scale -


  • Revenue is 27148 Rs Cr; Annual Growth is 17 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 15 %
  • Ebitda is 8985 Rs Cr; Annual Growth is 23 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 26 %
  • PAT is 5026 Rs Cr; Continuous Growth over 3 years; in Top Quartile
  • Quarterly Revenue is 7802 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile
  • PBT is 1307 Rs Cr; in Top Quartile; 5 Year CAGR is 24 %

Profitability -


  • PBDIT Margin is 33.09 %; Continuous Growth over 3 years; 5 Year CAGR is 9 %
  • PAT Margin is 18.51 %; 5 Year CAGR is -11 %

Return -


  • ROA is 9.61 %; Annual Decline is -21 %; Continuous Decline over 3 years
  • ROE is 18.58 %; Continuous Decline over 3 years
  • Asset Turnover is 61 %; Continuous Decline over 3 years

Efficiency -


  • Operating cash flow is 2117 Rs Cr; in Top Quartile; Annual Decline is -69 %
  • Inventory Turnover Ratio is 5.67; 5 Year CAGR is 54 %
  • Current Ratio is 1.27; Annual Decline is -33 %; Continuous Decline over 3 years; in Bottom Quartile
  • Quick Ratio is 0.91; Annual Decline is -37 %; Continuous Decline over 3 years

Solvancy -


  • Debt/Equity is 0.43; Annual Growth is 231 %; Continuous Growth over 3 years; in Top Quartile
  • Total Debt is 11770 Rs Cr; Annual Growth is 271 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 29 %
  • Contingent Liabilities is 2807 Rs Cr; Annual Growth is 97 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 23 %
  • Long term Debt is 3188 Rs Cr; in Top Quartile; 5 Year CAGR is 72 %

Quality -


  • Exceptional Items/PBT is -8 %; Annual Decline is -114 %; Continuous Decline over 3 years; in Bottom Quartile
  • Current Tax/PAT is 27 %; Annual Decline is -38 %; 5 Year CAGR is 30 %
  • Change in Inventories/Total Expenses is -4 %; Annual Decline is -304 %; in Bottom Quartile
  • Operating cashflow/ebitda is 24 %; Annual Decline is -75 %; in Bottom Quartile; 5 Year CAGR is -21 %
  • Operating cashflow/PAT is 42 %; Annual Decline is -71 %; in Bottom Quartile
  • Other Expenses/Total Expenses is 34 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Jignesh Bhatt Appointed Director of Finance at ZyVet Animal Health
Nifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%
Zydus Lifesciences (NSE:ZYDUSLIFE): What Is Behind the Duplicate Share Certificate Notice?
F&O Stocks to Buy: CDSL, Zydus Life, Sun Pharma Levels
Top 2 stocks to buy for short-term: Zydus Life, Whirlpool by Nagaraj Shetti
Trade Spotlight: How should you trade Chennai Petroleum, Sansera Engineering, Zydus Lifesciences, Indian...
Zydus Lifesciences Sees Sharp Open Interest Surge Signalling Market Positioning Shift
Astec LifeSciences Reports ?37.4 Crore Loss In Q2 FY27 As Total Income Declines By 3%
Top stocks to buy in F&O segment: CDSL, Zydus Lifesciences, Sun Pharma by Jay Thakkar for near-term | Check targets
Trade Spotlight: How should you trade BSE, Mankind Pharma, Bajaj Finserv, Bharti Airtel, Zydus...
Zydus Lifesciences Faces 5 US FDA Observations At Moraiya Manufacturing Facility
Zydus Lifesciences Faces 5 US FDA Observations at Moraiya Plant; Could US Sales Be at Risk?
Zydus Lifesciences In Focus As US FDA Flags Data Integrity, Quality Control Issues At Gujarat Plant